Soluble apoE/Aβ complex: Mechanism and therapeutic target for APOE4-induced AD risk

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Tai, Leon M ^a   Mehra, Shipra ^a   Shete, Varsha ^a   Estus, Steve ^b   Rebeck, G William ^c   Bu, Guojun ^d   Ladu, Mary Jo ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Apolipoprotein E; Apolipoprotein E amyloid beta complex; Lipidation; Lipoprotein; Oligomeric amyloid beta

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A BETA; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CELL NUCLEUS RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DIETARY INTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOTHESIS; LIPID METABOLISM; LIPIDATION; MODULATION; MOLECULAR INTERACTION; NERVE DEGENERATION; NONHUMAN; PROTEIN AGGREGATION; REVIEW; RISK ASSESSMENT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN E4; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROTEIN BINDING; RISK FACTORS; SOLUBILITY;

EID: 84891502796     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-2     Document Type: Review

References (114)

1. Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. Reitz C, Mayeux R, J Alzheimers Dis 2010 19 229 251 20061642
2. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Leoni V, Clin Chem Lab Med 2011 49 375 383 21388338
3. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Liu CC, Kanekiyo T, Xu H, Bu G, Nat Rev Neurol 2013 9 106 118 10.1038/nrneurol. 2012.263 23296339
4. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, et al. J Biol Chem 2013 288 5914 5926 10.1074/jbc.M112.442103 23293020
5. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J, Am J Pathol 1999 155 853 862 10.1016/S0002-9440(10)65184-X 10487842 (Pubitemid 29426831)
6. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL, Ann Neurol 1999 46 860 866 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M 10589538
7. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Wang J, Dickson DW, Trojanowski JQ, Lee VM, Exp Neurol 1999 158 328 337 10.1006/exnr.1999.7085 10415140 (Pubitemid 29382824)
8. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Tomic JL, Pensalfini A, Head E, Glabe CG, Neurobiol Dis 2009 35 352 358 10.1016/j.nbd.2009.05.024 19523517
9. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, Proc Natl Acad Sci USA 2011 108 5819 5824 10.1073/pnas.1017033108 21421841
10. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE, J Biol Chem 1996 271 4077 4081 10.1074/jbc.271.8.4077 8626743
11. Resolving controversies on the path to Alzheimer's therapeutics. Selkoe DJ, Nat Med 2011 17 1060 1065 10.1038/nm.2460 21900936
12. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, et al. J Biol Chem 2012 287 41774 41786 10.1074/jbc.M112.407957 23060451
13. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. Thal DR, Griffin WS, Braak H, J Cell Mol Med 2008 12 1848 1862 10.1111/j.1582-4934.2008.00411.x 18624777
14. The development of amyloid beta protein deposits in the aged brain. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H, Sci Aging Knowledge Environ 2006 2006 e1 16525193
15. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Haass C, Selkoe DJ, Nat Rev Mol Cell Biol 2007 8 101 112 10.1038/nrm2101 17245412 (Pubitemid 46432529)
16. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Klein WL, Neurochem Int 2002 41 345 352 10.1016/S0197-0186(02)00050-5 12176077
17. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ, J Neurosci 2011 31 15861 15869 10.1523/JNEUROSCI.3272-11.2011 22049429
18. Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, et al. Sci Transl Med 2013 5 212ra161 10.1126/scitranslmed.3007000 24259049
19. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH, Brain 2013 136 1383 1398 10.1093/brain/awt062 23576130
20. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. Hardy J, J Alzheimers Dis 2006 9 151 153 16914853 (Pubitemid 44253307)
21. Soluble Abeta oligomer production and toxicity. Larson ME, Lesne SE, J Neurochem 2012 120 Suppl 1 125 139
22. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM, J Neurosci 2011 31 18007 18012 10.1523/JNEUROSCI.3773-11.2011 22159114
23. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM, J Neurosci 2009 29 6771 6779 10.1523/JNEUROSCI.0887- 09.2009 19474305
24. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, et al. Neurology 2009 72 1487 1494 10.1212/WNL.0b013e3181a2e8d0 19339712
25. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H, Henriksen G, Klunk WE, Mathis CA, Perneczky R, et al. Biol Psychiatry 2010 68 879 884 10.1016/j.biopsych.2010. 05.013 20598287
26. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, et al. Brain 2012 135 2155 2168 10.1093/brain/aws127 22637583
27. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, et al. J Neurosci 2012 32 15181 15192 10.1523/JNEUROSCI.1542-12.2012 23100439
28. AD synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly. Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, Cole GM, Gylys KH, Neurobiol Aging 2012 33 1545 1555 10.1016/j.neurobiolaging.2011.05.011 21741125
29. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD, Proc Natl Acad Sci U S A 1993 90 1977 1981 10.1073/pnas.90.5.1977 8446617 (Pubitemid 23069980)
30. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD, Proc Natl Acad Sci USA 1993 90 8098 8102 10.1073/pnas.90.17.8098 8367470 (Pubitemid 23260862)
31. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B, Biochem Biophys Res Commun 1993 192 359 365 10.1006/bbrc.1993.1423 8484748 (Pubitemid 23227331)
32. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. J Clin Invest 1994 94 860 869 10.1172/JCI117407 8040342
33. Isoform-specific binding of apolipoprotein E to beta-amyloid. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE, J Biol Chem 1994 269 23403 23406 8089103
34. Effect of apolipoprotein E isoforms on b-amyloid induced toxicity in rat primary hippocampal cultures. Falduto M, LaDu MJ, Manelli AM, Getz GS, Puttfarcken PS, Soc Neurosci Abst 1995 21 1716
35. Apolipoprotein E carboxy-terminal fragments are complexed to amyloids A and L. Castano EM, Prelli F, Pras M, Frangione B, J Biol Chem 1995 270 17610 17615 10.1074/jbc.270.29.17610 7615568
36. Characterization of stable complexes involving apolipoprotein E and the amyloid ß peptide in Alzheimer's disease brain. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C, Neuron 1995 15 219 228 10.1016/0896-6273(95)90079-9 7619525
37. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Golabek A, Marques MA, Lalowski M, Wisniewski T, Neurosci Lett 1995 191 79 82 10.1016/0304-3940(95)11565-7 7659297
38. The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. Golabek AA, Soto C, Vogel T, Wisniewski T, J Biol Chem 1996 271 10602 10606 10.1074/jbc.271.18.10602 8631862 (Pubitemid 26145794)
39. Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. Shuvaev VV, Siest G, FEBS Lett 1996 383 9 12 10.1016/0014-5793(96)00206-2 8612800 (Pubitemid 26092627)
40. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Chan W, Fornwald J, Brawner M, Wetzel R, Biochemistry 1996 35 7123 7130 10.1021/bi952852v 8679539 (Pubitemid 26182103)
41. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Zhou Z, Smith JD, Greengard P, Gandy S, Mol Med 1996 2 175 180 8726460 (Pubitemid 26421987)
42. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. LaDu MJ, Lukens JR, Reardon CA, Getz GS, J Neurosci Res 1997 49 9 18 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H 9211985 (Pubitemid 27291172)
43. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN, J Neurochem 1997 68 721 725 9003062 (Pubitemid 27044736)
44. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Aleshkov S, Abraham CR, Zannis VI, Biochem 1997 36 10571 10580 10.1021/bi9626362 (Pubitemid 27374151)
45. Specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Pillot T, Goethals M, Vanloo B, Lins L, Brasseur R, Vandekerckhove J, Rosseneu M, Euro J Biochem 1997 243 650 659 10.1111/j.1432-1033.1997.00650.x (Pubitemid 27073431)
46. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller JK, Zaccheo D, Gambetti P, Tabaton M, Proc Natl Acad Sci USA 1998 95 15598 15602 10.1073/pnas.95.26.15598 9861015 (Pubitemid 29018745)
47. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. Pillot T, Goethals M, Najib J, Labeur C, Lins L, Chambaz J, Brasseur R, Vandekerckhove J, Rosseneu M, J Neurochem 1999 72 230 237 9886074 (Pubitemid 29013897)
48. Higher avidity binding of apolipoprotein (E-AII) complex than of apolipoprotein E monomer to beta-amyloid. Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y, Katsuyama T, J Neurosci Res 1999 58 301 307 10.1002/(SICI)1097-4547(19991015)58:2<301::AID-JNR10>3.0.CO;2-9 10502286 (Pubitemid 29471431)
49. Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). Aleshkov SB, Li X, Lavrentiadou SN, Zannis VI, Biochemistry 1999 38 8918 8925 10.1021/bi982002q 10413465 (Pubitemid 29334653)
50. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. Golabek AA, Kida E, Walus M, Perez C, Wisniewski T, Soto C, Biophys J 2000 79 1008 1015 10.1016/S0006-3495(00)76354-5 10920030 (Pubitemid 30626191)
51. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, LaDu MJ, Rostagno A, et al. Biochem J 2000 348 Pt 2 359 365 10816430 (Pubitemid 30345209)
52. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. Drouet B, Fifre A, Pincon-Raymond M, Vandekerckhove J, Rosseneu M, Gueant JL, Chambaz J, Pillot T, J Neurochem 2001 76 117 127 10.1046/j.1471-4159.2001.00047.x 11145984 (Pubitemid 32044374)
53. Human cerebrospinal fluid apolipoprotein E isoforms are apparently inefficient at complexing with synthetic Alzheimer's amyloid-[beta] peptide (A[beta] 1-40) in vitro. Zhou Z, Relkin N, Ghiso J, Smith JD, Gandy S, Mol Med 2002 8 376 381 12393935 (Pubitemid 35346217)
54. Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges. Bentley NM, LaDu MJ, Rajan C, Getz GS, Reardon CA, Biochem J 2002 366 273 279 12015813 (Pubitemid 34971827)
55. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. Gylys KH, Fein JA, Tan AM, Cole GM, J Neurochem 2003 84 1442 1451 10.1046/j.1471-4159.2003.01643.x 12614344 (Pubitemid 36343610)
56. ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ, J Mol Neurosci 2004 23 235 246 10.1385/JMN:23:3:235 15181252
57. Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interaction. Phu MJ, Hawbecker SK, Narayanaswami V, J Neurosci Res 2005 80 877 886 10.1002/jnr.20503 15880461 (Pubitemid 40961300)
58. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB, Chem Phys Lipids 2005 137 52 61 10.1016/j.chemphyslip.2005.06.005 16140289 (Pubitemid 41405832)
59. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, et al. Neurobiol Dis 2005 19 66 76 10.1016/j.nbd.2004.11.005 15837562 (Pubitemid 40544724)
60. A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers. Wellnitz S, Friedlein A, Bonanni C, Anquez V, Goepfert F, Loetscher H, Adessi C, Czech C, J Neurochem 2005 94 1351 1360 10.1111/j.1471-4159.2005.03295.x 16011742 (Pubitemid 41232590)
61. A differential association of Apolipoprotein E isoforms with the amyloid-beta oligomer in solution. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, Jin LW, Voss JC, Proteins 2011 79 402 416 10.1002/prot.22891 21069870
62. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V, FASEB J 2011 25 1585 1595 10.1096/fj.10-175976 21266538
63. Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. LaDu MJ, Munson GW, Jungbauer L, Getz GS, Reardon CA, Tai LM, Yu C, Biochim Biophys Acta-Molecular and Cell Biology of Lipids 1821 2012 295 302
64. Binding of apolipoprotein E inhibits the oligomer growth of amyloid-beta peptide in solution as determined by fluorescence cross-correlation spectroscopy. Ly S, Altman R, Petrlova J, Lin Y, Hilt S, Huser T, Laurence TA, Voss JC, J Biol Chem 2013 288 11628 11635 10.1074/jbc.M112.411900 23430745
65. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM, Proc Natl Acad Sci U S A 2013 110 1807 1816 10.1073/pnas.1220484110 23620513
66. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT, J Biol Chem 1995 270 9039 9042 10.1074/jbc.270.16.9039 7721816
67. Nascent astrocyte particles differ from lipoproteins in CSF. LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM, J Neurochem 1998 70 2070 2081 9572293 (Pubitemid 28207831)
68. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ, J Biol Chem 1996 271 32916 32922 10.1074/jbc.271.51.32916 8955133 (Pubitemid 27008725)
69. Effect of apolipoprotein AII on the interaction of apolipoprotein E with beta-amyloid: some apo(E-AII) complexes inhibit the internalization of beta-amyloid in cultures of neuroblastoma cells. Yamauchi K, Tozuka M, Hidaka H, Nakabayashi T, Sugano M, Kondo Y, Nakagawara A, Katsuyama T, J Neurosci Res 2000 62 608 614 10.1002/1097-4547(20001115)62:4<608::AID-JNR16>3.0.CO;2-4 11070505
70. Lipoproteins in the central nervous system. LaDu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS, Ann N Y Acad Sci 2000 903 167 175 10.1111/j.1749-6632.2000.tb06365.x 10818504 (Pubitemid 30251555)
71. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y, J Neurosci 2006 26 4985 4994 10.1523/JNEUROSCI.5476-05.2006 16687490 (Pubitemid 44315280)
72. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D, Clin Chim Acta 1991 196 167 176 10.1016/0009-8981(91)90070-S 2029783
73. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K, Neurochem Res 2000 25 511 517 10.1023/A:1007516210548 10823584 (Pubitemid 30317684)
74. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, et al. Mol Neurodegener 2007 2 7 10.1186/1750-1326-2-7 17430597 (Pubitemid 46698827)
75. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Fagan AM, Younkin LH, Morris JC, Fryer JD, Cole TG, Younkin SG, Holtzman DM, Ann Neurol 2000 48 201 210 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X 10939571 (Pubitemid 30617039)
76. Proposed mechanism for lipoprotein remodelling in the brain. Yu C, Youmans KL, LaDu MJ, Biochim Biophys Acta 1801 2010 819 823
77. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M, J Biol Chem 2002 277 29919 29926 10.1074/jbc.M203934200 12042316
78. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, et al. J Neurosci 2008 28 11445 11453 10.1523/JNEUROSCI.1972-08.2008 18987181
79. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, et al. J Clin Invest 2008 118 671 682 18202749 (Pubitemid 351206556)
80. The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, et al. J Biol Chem 2005 280 43243 43256 10.1074/jbc.M508781200 16207707 (Pubitemid 43049291)
81. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM, J Biol Chem 2005 280 43236 43242 10.1074/jbc.M508780200 16207708 (Pubitemid 43049290)
82. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R, J Neurosci 2012 32 13125 13136 10.1523/JNEUROSCI.1937-12.2012 22993429
83. Amyloid-beta42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, Ladu MJ, J Neurosci Methods 2011 196 51 59 10.1016/j.jneumeth.2010.12.025 21219931
84. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH, J Biol Chem 2002 277 50380 50385 10.1074/jbc.M204898200 12393895 (Pubitemid 36042188)
85. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH, Biochemistry 2000 39 11657 11666 10.1021/bi000099m 10995233
86. Apolipoprotein E and cholesterol in aging and disease in the brain. de Chaves EP, Narayanaswami V, Future Lipidol 2008 3 505 530 10.2217/17460875.3.5. 505 19649144
87. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. Sci Transl Med 2011 3 89ra57 21715678
88. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV, J Clin Invest 2008 118 4002 4013 10.1172/JCI36663 19033669
89. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM, Nat Med 2004 10 719 726 10.1038/nm1058 15195085 (Pubitemid 38937637)
90. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE, J Neurosci 2009 29 4252 4262 10.1523/JNEUROSCI.5572-08.2009 19339619
91. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM, J Biol Chem 2012 287 13959 13971 10.1074/jbc.M111.288746 22383525
92. The role of astrocytes in amyloid beta-protein toxicity and clearance. Thal DR, Exp Neurol 2012 236 1 5 10.1016/j.expneurol.2012.04.021 22575598
93. ApoE promotes the proteolytic degradation of Abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al. Neuron 2008 58 681 693 10.1016/j.neuron.2008.04.010 18549781 (Pubitemid 351778466)
94. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ, J Neurosci 2000 20 1657 1665 10684867 (Pubitemid 30220363)
95. Intraneuronal Abeta accumulation and neurodegeneration: lessons from transgenic models. Wirths O, Bayer TA, Life Sci 2012 91 1148 1152 10.1016/j.lfs.2012.02.001 22401905
96. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G, J Biol Chem 2012 287 44593 44601 10.1074/jbc.M112.420224 23132858
97. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier. Bachmeier C, Beaulieu-Abdelahad D, Crawford F, Mullan M, Paris D, J Mol Neurosci 2013 49 270 276 10.1007/s12031-012-9866-6 22890420
98. Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE epsilon4 allele. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO, PLoS One 2012 7 41636 10.1371/journal.pone.0041636 22848551
99. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R, Glia 2010 58 1235 1246 20544859
100. Intracellular amyloid-beta in Alzheimer's disease. LaFerla FM, Green KN, Oddo S, Nat Rev 2007 8 499 509 10.1038/nrn2168 (Pubitemid 46985362)
101. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Wisniewski T, Frangione B, Neurosci Lett 1992 135 235 238 10.1016/0304-3940(92)90444-C 1625800
102. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T, Am J Pathol 2004 165 937 948 10.1016/S0002-9440(10)63355-X 15331417 (Pubitemid 39129300)
103. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T, Proc Natl Acad Sci U S A 2006 103 18787 18792 10.1073/pnas.0604011103 17116874 (Pubitemid 44913488)
104. Targeting Alzheimer's pathology through PPARgamma signaling: modulation of microglial function. Lourenco MV, Ledo JH, J Neurosci 2013 33 5083 5084 10.1523/JNEUROSCI.0172-13.2013 23516274
105. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Mandrekar-Colucci S, Karlo JC, Landreth GE, J Neurosci 2012 32 10117 10128 10.1523/JNEUROSCI.5268-11.2012 22836247
106. PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT, J Neurosci 2012 32 17321 17331 10.1523/JNEUROSCI.1569-12.2012 23197723
107. Selective liver X receptor modulators (SLiMs): what use in human health? Viennois E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, Baron S, Mol Cell Endocrinol 2012 351 129 141 10.1016/j.mce.2011.08.036 21907760
108. Comment on «ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models» Fitz NF, Cronican AA, Lefterov I, Koldamova R, Science 2013 340 924
109. Comment on «ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models» Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM, Science 2013 340 924
110. Comment on «ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models» Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, et al. Science 2013 340 924
111. Comment on «ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models» Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS, Science 2013 340 924
112. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, et al. Science 2012 335 1503 1506 10.1126/science.1217697 22323736
113. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, et al. JAMA Neurol 2013 1 9
114. Blocking the apolipoprotein E/amyloid-beta interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. Yang J, Ji Y, Mehta P, Bates KA, Sun Y, Wisniewski T, J Alzheimers Dis 2011 24 269 285 21239853